Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...

Personalized mRNA vaccines show promise as a pancreatic cancer treatment, according to a small, early stage trial published ...

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study ...

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

Pancreatic cancer is the 10th deadliest form of cancer in the United States, according to the National Cancer Institute.

Penn researchers are developing new treatments using mRNA technology to combat a range of diseases, namely celiac disease ...

A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease ...

The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...

an experimental approach to treating the cancer with a messenger RNA (mRNA)-based therapeutic vaccine "continues to show potential" in reducing the risk of the disease returning after surgery ...